Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
企業コードDERM
会社名Journey Medical Corp
上場日Nov 12, 2021
最高経営責任者「CEO」Mr. Claude Maraoui
従業員数41
証券種類Ordinary Share
決算期末Nov 12
本社所在地9237 E Via De Ventura Blvd., Suite 105
都市SCOTTSDALE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号85258
電話番号14804346670
ウェブサイトhttps://journeymedicalcorp.com/
企業コードDERM
上場日Nov 12, 2021
最高経営責任者「CEO」Mr. Claude Maraoui
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし